A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
On July 21, President Donald Trump announced his latest set of sweeping tariffs on the pharmaceutical industry: a 200% levy on imported generic drugs by the year 2029.
